Vnitr Lek 2021, 67(8):E19-E22 | DOI: 10.36290/vnl.2021.130

Tumor induced osteomalacia

Lenka Filipová1, Ivica Lazúrová2
1 Endokrinologická ambulancia, Nemocnica Agel Košice Šaca, a. s.
2 IK UNLP a LF UPJŠ Košice

Tumor induced osteomalacia (TIO) is a rare paraneoplastic syndrome typically caused by small endocrine tumors that secrete fibroblast growth factor 23(FGF23). TIO is clinically characterized by progressive muskuloskeletal pain, fatigue, proximal muscle weakness, and multiple fractures that lead to long-term disability. Due to the non-specific symptoms of the disease, it may take several years for them to be properly diagnosed and treated, so it is important to better inform about this rare paraneoplastic syndrome. Key word: FGF23, hypophosphataemia, tumor induced osteomalacia.

Keywords: FGF23, hypofosfatémia, tumorom indukovaná hypofosfatémia.

Published: December 9, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Filipová L, Lazúrová I. Tumor induced osteomalacia. Vnitr Lek. 2021;67(8):E19-22. doi: 10.36290/vnl.2021.130.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT. Tumor‑Induced Osteomalacia. Calcif Tissue Int. 2021 Jan;108(1):128-142. Go to original source... Go to PubMed...
    2. Li X, Jiang Y, Huo L, et al. Nonremission and Recurrent Tumor‑Induced Osteomalacia: A Retrospective Study. J Bone Miner Res. 2020;35(3):469-477. Go to original source... Go to PubMed...
    3. Agaimy A, Michal M, Chiosea S, Petersson F, Hadravsky L, Kristiansen G, et al. Phosphaturic mesenchymal tumors: clinicopathologic, immunohistochemical and molecular analysis of 22 cases expanding their morphologic and immunophenotypic spectrum. The American Journal of Surgical Pathology. 2017;41(10):1371-1380. Go to original source... Go to PubMed...
    4. Huang X, Jiang Y, Xia W. FGF23 and Phosphate Wasting Disorders. Bone Res. 2013 Jun 28;1(2):120-32. Go to original source...
    5. Yin Z, Du J, Yu F, Xia W. Tumor‑induced osteomalacia. Osteoporos Sarcopenia. 2018;4(4):119-127. Go to original source... Go to PubMed...
    6. Feng J, Jiang Y, Wang O, Li M, Xing X, Huo L, Li F, Yu W, Zhong DR, Jin J, Liu Y, Qi F, Lv W, Zhou L, Meng XW, Xia WB. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J. 2017 Jul 28;64(7):675-683. Go to original source... Go to PubMed...
    7. Tiefenbach, M, Scheel, M, Maier A et al. Osteomalazie - Klinik, Diagnostik und Therapie. Z Rheumatol 2018;77, 703-718 Go to original source... Go to PubMed...
    8. Tesár TO. An expanding family of hypophoshatemic syndromes. J Bone Miner Metab 2012; 30 : 1-9. Go to original source...
    9. Svačina, Š. et al. Poruchy metabolizmu a výživy. Praha:Galen 2010.106-109. ISBN 978-80-7262-676-2.
    10. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor‑induced osteomalacia. Endocr Relat Cancer. 2011;18(3):R53-77. Go to original source... Go to PubMed...
    11. Zhang J., Zhu Z., Zhong D., Dang Y., Xing H., Du Y. 68Ga DOTATATE PET/CT is an accurate imaging modality in the detection of culprit tumors causing osteomalacia. Clin Nucl Med. 2015;40:642-646. Go to original source... Go to PubMed...
    12. Jiang Y, Hou G, Cheng W. Performance of 68Ga‑DOTA‑SST PET/CT, octreoscan SPECT/CT and 18 F‑FDG PET/CT in the detection of culprit tumors causing osteomalacia: a meta‑analysis. Nucl Med Commun. 2020 Apr;41(4):370-376. Go to original source... Go to PubMed...
    13. Athonvarangkul D, Insogna KL. New Therapies for Hypophosphatemia‑Related to FGF23 Excess. Calcif Tissue Int. 2021 Jan;108(1):143-157. Go to original source... Go to PubMed...
    14. Padidela R, Nilsson O, Makitie O, Beck‑Nielsen S, Ariceta G, Schnabel D, Brandi ML, Boot A, Levtchenko E, Smyth M, Jandhyala R, Mughal Z. The international X‑linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study. Orphanet J Rare, DiS. 2020 Jun 30;15(1):172. Go to original source... Go to PubMed...
    15. Song K, Yan Q, Yang Y, et al. Fanconi syndrome induced by adefovir dipivoxil: a case report and clinical review. J Int Med Res. 2020;48(10):300060520954713. Go to original source...
    16. Gou M, Ma Z. Osteomalacia, renal Fanconi syndrome, and bone tumor. J Int Med Res. 2018;46(8):3487-3490. Go to original source...
    17. Minisola S, Peacock M, Fukumoto S, et al. Tumour‑induced osteomalacia. Nat Rev Dis Primers. 2017;3:17044. Go to original source... Go to PubMed...
    18. Chong WH, Andreopoulou P, Chen CC, Reynolds J, Guthrie L, Kelly M, Gafni RI, Bhattacharyya N, Boyce AM, El‑Maouche D, Crespo DO, Sherry R, Chang R, Wodajo FM, Kletter GB, Dwyer A, Collins MT. Tumor localization and biochemical response to cure in tumor‑induced osteomalacia. J Bone Miner Res. 2013 Jun;28(6):1386-98. Go to original source... Go to PubMed...
    19. Piemonte S, Romagnoli E, Cipriani C, De Lucia F, Pilotto R, Diacinti D, Pepe J, Minisola S. Six‑year follow‑up of a characteristic osteolytic lesion in a patient with tumor‑induced osteomalacia. Eur J Endocrinol. 2013 Nov 29;170(1):K1-4. Go to original source... Go to PubMed...
    20. Mishra SK, Kuchay MS, Sen IB, Garg A, Baijal SS, Mithal A. Successful Management Of Tumor‑Induced Osteomalacia with Radiofrequency Ablation: A Case Series. JBMR Plus. 2019 Feb 28;3(7):e10178. Go to original source... Go to PubMed...
    21. Dahir, K., Zanchetta, M. B., Stanciu, I., Robinson, C., Lee, J. Y., Dhaliwal, R., Charles, J., Civitelli, R., Roberts, M. S., Krolczyk, S., & Weber, T. Diagnosis and Management of Tumor‑induced Osteomalacia: Perspectives From Clinical Experience. Journal of the Endocrine Society, 1021;5(9), bvab099. Go to original source...
    22. Jan De Beur S, Miller P, Weber T, et al. Burosumab improves the biochemical, skeletal, and clinical symptoms of tumor‑induced osteomalacia syndrome. J Endocr Soc. 2019;3(Suppl_1):OR13-1.
    23. Imanishi Y, Ito N, Rhee Y, et al. Interim analysis of a phase 2 open‑label trial assessing burosumab efficacy and safety in patients with tumor‑induced osteomalacia. J Bone Miner Res. 2021;36(2):262-270. Go to original source... Go to PubMed...
    24. Hartley IR, Miller CB, Papadakis GZ, et al. Targeted FGFR blockade for the treatment of tumor‑induced osteomalacia. N Engl J Med. 2020;383(14):1387-1389. Go to original source...
    25. Cundy T, Que L, Hassan IM, Hughes L. Bisphosphonate‑Induced Deterioration of Osteomalacia in Undiagnosed Adult Fanconi Syndrome. JBMR Plus. 2020 Jun 5;4(8):e10374. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.